Primary entity: Certificate of analysis (COA) · Also known as: COA; lot COA; HPLC purity certificate (marketing language)

A certificate of analysis (COA) is a document that claims analytical results for a material lot — often identity and purity metrics (e.g., HPLC). A COA is only as meaningful as the lab, methods, sample handling, and whether it matches your vial. It is not automatic proof of sterility, correct fill amount, absence of harmful impurities, or human clinical safety.

Key takeaways

  • COA = claimed test paperwork for a lot.
  • High “% purity” ≠ safe to inject / ≠ approved drug.
  • We explain concepts; we do not authenticate vendor PDFs or recommend sellers.
  • See Research peptides

Questions this page answers

  1. Definition
  2. Limits of COA literacy
  3. Related reading

Definition

In chemical supply literacy, a COA summarizes tests performed (or claimed) on a batch: for peptides, marketing often highlights purity percentage and identity methods. Legitimate pharmaceutical quality systems are far broader than a single purity number.

Limits of COA literacy

  • Paperwork can be mismatched, outdated, or fabricated.
  • Purity assays do not equal sterility assurance for injection.
  • Approved drugs rely on regulated manufacturing + labeling — not gray-market COA culture.
  • This site will not turn COA shopping into a buy guide.

Frequently asked questions

What does COA mean for peptides?

A document claiming analytical results for a lot — commonly identity/purity style metrics in vendor marketing.

Does a 99% COA mean the vial is safe?

No. Even a real purity result would not establish clinical safety, sterility, or that your vial matches the PDF.

Do you verify vendor COAs?

No. We teach literacy limits; we do not provide sourcing or authentication services.

Sources

  1. U.S. Food and Drug Administration. Facts About the Current Good Manufacturing Practice (CGMP). Quality systems and testing expectations for approved drugs; a vendor certificate of analysis is not a substitute for an approved application. Accessed November 10, 2026.
  2. U.S. Food and Drug Administration. Human drug compounding and bulk drug substances used in compounding under section 503A. Accessed November 10, 2026.
  3. Peptide Tutorials. Research peptides; Disclaimers.
Disclaimer

Educational content only — not medical advice or product authentication. We do not sell peptides.